Latest News and Press Releases

ANN ARBOR, Mich., Feb. 24, 2023 (GLOBE NEWSWIRE) -- With a focus on science and clinical evidence, Esperion today announced the launch of the website, esperionscience.com. This website, geared...

CONCORD, N.C., Jan. 11, 2023 (GLOBE NEWSWIRE) --  RFK Racing has announced that Esperion Therapeutics, a Michigan-based pharmaceutical company, has partnered with the team for a multi-year agreement...

– Based on the robustness of the CLEAR Outcomes data across primary and secondary endpoints, Company anticipates global regulatory submissions in 1H 2023 and believes it is entitled to receive...

– Positive CLEAR Outcomes data to be presented as a Late-Breaking Clinical Trial (LBCT) at ACC.23/WCC on March 4, 2023 – – Bempedoic acid becomes the first ATP citrate lyase inhibitor and first oral...

– Demonstrates statistically significant and clinically meaningful results – – Bempedoic acid becomes the first ATP citrate lyase inhibitor and first oral non-statin to meet the major adverse...

ANN ARBOR, Mich., Nov. 16, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that Ben Halladay, MBA, has been promoted to the role of Chief Financial Officer (CFO) from his prior...

– Event to Include Expert-Led Discussions on State of Cardiovascular Disease Treatments and Remaining Unmet Needs – – Esperion Leadership Will Provide Overview of its Investigational Pipeline,...

ANN ARBOR, Mich., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that President and CEO, Sheldon Koenig, will present at the Jefferies London Healthcare Conference on...

– CLEAR Outcomes Trial Achieved Last Patient Last Visit in October Ensuring Timely Trial Completion – – Remain On Track to Report Topline Results in January 2023, with Full Results Targeted to be...

– Overview of its investigational pipeline, planned scientific focus, and future growth drivers – – Wednesday, November 9th @ 10amET – ANN ARBOR, Mich., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Esperion...